Lipid Screening and Dyslipidemia in Children with Congenital Heart Disease
-
By
-
Phillip S. Cheng
-
Jonathan A. Wheeler
-
Aaron T. Walsh
-
Chance R. Alvarado
-
Kan N. Hor
-
Andrew H. Tran
-
July 4, 2026
-
Clinical Scorecard: Assessment of Lipid Levels and Dyslipidemia in Pediatric Patients with Congenital Heart Defects
At a Glance
| Category | Detail |
|---|
| Condition | Dyslipidemia in Pediatric Patients with Congenital Heart Defects |
| Key Mechanisms | Increased risk of atherosclerosis and cardiovascular disease due to dyslipidemia. |
| Target Population | Children aged 9-18 years with congenital heart defects. |
| Care Setting | Pediatric cardiology outpatient clinics. |
Key Highlights
- Dyslipidemia increases cardiovascular disease risk starting in childhood.
- AAP recommends lipid screening for children at ages 9-11 and 17-21.
- Only 18-31% of children with congenital heart disease underwent lipid screening.
- Lipid values in childhood can predict adult lipid levels.
- Low adherence to lipid screening guidelines among pediatricians.
Guideline-Based Recommendations
Diagnosis
- Lipid screening should be performed at ages 9-11 and 17-21 years.
Management
- Identify and treat dyslipidemia to reduce future cardiovascular risk.
Monitoring & Follow-up
- Regular follow-up lipid panels for children with congenital heart defects.
Risks
- Increased lifetime risk of cardiovascular disease in children with congenital heart defects.
Patient & Prescribing Data
Children with congenital heart defects aged 9-18 years.
Limited data on dyslipidemia rates among screened children with congenital heart defects.
Clinical Best Practices
- Ensure adherence to AAP lipid screening recommendations.
- Utilize electronic medical records for tracking lipid levels.
- Educate healthcare providers on the importance of early lipid screening.
Related Resources & Content
